What to Know About the USPTO’s Duty of Candor Guidance Regarding FDA Submissions
Fish & Richardson Trademark & Copyright Thoughts
SEPTEMBER 16, 2022
Information and statements” may include, among other items, information that “refutes, or is inconsistent with, a position that the applicant takes in” either “opposing an argument of unpatentability relied on by the Office” or “asserting an argument of patentability.”. the party has a duty to submit the information to the USPTO.”.
Let's personalize your content